Personalized weight-loss care for breast cancer survivors explored in clinical trial
A personalized approach to obesity treatment may help breast cancer survivors improve their long-term health by identifying early which patients need more than behavioral and lifestyle interventions alone, according to a Johns Hopkins Kimmel Cancer Center-led clinical trial.
A clinical trial led by Johns Hopkins Kimmel Cancer Center researchers explored the potential of personalized weight-loss care for breast cancer survivors. The Adaptive Nutrition and Exercise Weight Loss (A-NEW) trial revealed that patients who did not lose at least 5% of their body weight after two months of a structured nutrition and exercise program were more likely to achieve this goal after adding an FDA-approved anti-obesity medication.
The study, published in Clinical Cancer Research, suggests that tailoring obesity treatment based on early patient response could improve long-term health outcomes for breast cancer survivors, who face higher risks of cancer recurrence, cardiovascular disease, poorer quality of life, and premature death due to obesity. While the medication was generally well tolerated, further research is needed to confirm these findings and determine if similar approaches using newer obesity medications can further enhance outcomes.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
